Scilex Holding (SCLX) Non-Current Debt (2021 - 2025)
Scilex Holding (SCLX) posted quarterly Non-Current Debt of $22.5 million for Q4 2025, up 2560.36% year-over-year from $845000.0 in Q4 2024, and up 2560.36% on a QoQ basis from $845000.0 in Q4 2024.
Scilex Holding (SCLX) Non-Current Debt (2021 - 2025) Analysis & Trends
Scilex Holding (SCLX) has reported Non-Current Debt for 5 consecutive years, with $22.5 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Non-Current Debt rose 2560.36% year-over-year to $22.5 million; the TTM figure through Dec 2025 stood at $22.5 million (up 2560.36% YoY), while the FY2025 annual figure was $22.5 million, up 2560.36% from the prior year.
- Non-Current Debt came in at $22.5 million for Q4 2025 at Scilex Holding, up from $845000.0 in the prior quarter.
- The five-year high for Non-Current Debt was $72.0 million in Q4 2021, with the low at $845000.0 in Q4 2024.
- Average Non-Current Debt over 5 years is $18.4 million, with a median of $15.3 million recorded in 2024.
- Across the five-year window, Non-Current Debt plunged 95.04% in 2024 and jumped 2560.36% in 2025, its largest moves.
- Year by year, Non-Current Debt stood at $72.0 million in 2021, then plunged by 95.87% to $3.0 million in 2022, then surged by 473.35% to $17.0 million in 2023, then slumped by 95.04% to $845000.0 in 2024, then surged by 2560.36% to $22.5 million in 2025.
- According to Business Quant data, Non-Current Debt over the past three periods registered $22.5 million, $845000.0, and $14.3 million for Q4 2025, Q4 2024, and Q3 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 39.37 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 37.53 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 64.53 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | -24.45 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 46.67 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 51.89 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 20.86 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 60.57 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Scilex Holding | 54.30 Mn | -95.62 Mn | 4.15 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 22.48 Mn |
| Dec 31, 2024 | 845,000.00 |
| Sep 30, 2024 | 14.33 Mn |
| Jun 30, 2024 | 29.03 Mn |
| Mar 31, 2024 | 16.32 Mn |
| Dec 31, 2023 | 17.04 Mn |
| Sep 30, 2023 | 6.93 Mn |
| Sep 30, 2022 | 2.97 Mn |
| Jun 30, 2022 | 2.00 Mn |
| Dec 31, 2021 | 72.04 Mn |